Clinical Trial Update: Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating irradiation with olaptesed pegol (NOX-A12) in MGMT unmethylated glioblastoma; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• NOX-A12 (olaptesed pegol) (olaptesed pegol)

Snippet

Sponsor: TME Pharma AG | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING